Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+1.34%
+0.35%
-2.06%
+1.92%
+1.51%
LLY
Eli Lilly and
$837.35
Login to see Eli Lilly and (LLY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Investors confidence is positive
Upgraded on attractively valued
Outperform the market
Chart
$738.64 (+13.36%)
$793.01 (+5.59%)
$746.06 (+12.24%)
$917.12 (-8.70%)
LLY has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
LLY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Earnings increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Investors confidence is positive
Expands stock buyback program
Future
Future
Earnings are forecast to grow
Outperform the market
LLY Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
LLY Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayLLY Earnings
The TTM reflects 12-month period, providing review of LLY financial performance.
The company financial health has moderately improved over the past year
Financial Score
NVO
59.56
+1.40%
SNY
50.87
+1.46%
PFE
27.29
+0.78%
NVS
132.44
+1.12%
ABBV
235.83
-0.27%
What is LLY current stock price?
What are LLY stock strengths?
What risks are associated with LLY stock?
When is LLY next earnings report?
What is LLY market cap and volume?
What is LLY's current Stock IQ?
Should I buy LLY stock right now?
Is LLY a Strong Buy right now?
What does a 'Strong Buy' rating mean for LLY?
What does a 'Strong Sell' rating mean for LLY?
What factors influence LLY's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+1.34%
+0.35%
-2.06%
+1.92%
+1.51%
LLY
Eli Lilly and
Current Price
$837.35
Stock Insights
Strengths
Earnings are forecast to grow
Investors confidence is positive
Upgraded on attractively valued
Outperform the market
Linked to LLY
NVO
59.56
+1.40%
SNY
50.87
+1.46%
PFE
27.29
+0.78%
NVS
132.44
+1.12%
ABBV
235.83
-0.27%
Login to unlock Eli Lilly and (LLY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$738.64 (+13.36%)
$793.01 (+5.59%)
$746.06 (+12.24%)
$917.12 (-8.70%)
LLY Analysts Opinion
LLY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Earnings increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Investors confidence is positive
Expands stock buyback program
Future
Future
Earnings are forecast to grow
Outperform the market
LLY Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
LLY Street view is extremely bullish and have positive views on the near-term outlook
LLY has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Average key support and resistance price levels.
Login to displayLLY Earnings
The TTM data reflects the most recent 12-month period, providing overview of LLY financial performance.
LLY Financial Health
The company financial health has moderately improved over the past year
Financial Score
LLY Latest Analysis
Eli Lilly and Company (LLY) Gets Upgraded to a Buy by CFRA. Eli Lilly and Company (NYSE:LLY) is one of the best medical stocks to buy now. In a report released on September 26 CFRA upgraded Eli Lilly and Company (NYSE:LLY) to a Buy setting a price target of $835.00. Eli Lilly and Company (NYSE:LLY) reported a 38% growth in its revenue for fiscal Q2 2025 to [….]
Today
LEXX: Biodistribution Study Results . By As we step into fall Lexaria Bioscience Corporation (NASDAQ:LEXX) continues to work on multiple GLP-1 trials. Most notably it reported the last patient-last visit for the Phase Ib study designated GLP-1-H24-4 and reported data from its rodent biodistribution study. It also closed a $4.0 million capital raise earlier this week. Activity in the obesity and GLP-1 agonist space has been robust in 2025 with a number of deals and new trial data announced. In th
Thu Oct 2, 2025
Eli Lilly Shares Cross Above 200 DMA. In trading on Wednesday shares of Eli Lilly (Symbol: LLY) crossed above their 200 day moving average of $783.30 changing hands as high as $800.34 per share. Eli Lilly shares are currently trading up about 4.1% on the day. The chart below shows the one year performance of LLY
Wed Oct 1, 2025
Top Stock Movers Now: Nike Eli Lilly Corteva AES and More.
Wed Oct 1, 2025
Eli Lilly and Company (LLY) Halts Experimental Study of Muscle-Sparing Obesity Drug. Eli Lilly and Company (NYSE:LLY) is among the 10 Best Money Making Stocks to Invest In. According to a United States registry of clinical trials the firm has halted an experimental drug study designed to stop obesity patients from excessive muscle loss due to undisclosed strategic business reasons. The company was testing Bimagrumab alone or in [….]
Tue Sep 30, 2025
Eli Lilly and Company (LLY) Opens a New Lilly Gateway Labs Innovation Hub in San Diego. With a strong profitability outlook Eli Lilly and Company (NYSE:LLY) secures a spot on our list of the 14 Stocks That Will Double in the Next 5 Years. On September 26 2025 Eli Lilly and Company (NYSE:LLY) opened a new Lilly Gateway Labs innovation hub in San Diego expanding its global network of facilities supporting early-stage biotech [….]
Tue Sep 30, 2025
This Is What Whales Are Betting On Eli Lilly. Investors with a lot of money to spend have taken a ish stance on ).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals we don'.t know. But when something this big happens with LLY it often means somebody knows something is about to happen.So how do we know what these investors just did? Today
Mon Sep 29, 2025
Eli Lilly: Strong Buy On Sustained Growth Expanding Moat And Pipeline Depth.
Mon Sep 29, 2025
LLY Gets EU Approval for Alzheimers Drug & FDA Nod to Cancer Therapy. Eli Lilly secures EU approval for Alzheimers drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.
Fri Sep 26, 2025
Eli Lilly upgraded at CFRA as minimal impact seen from pharma tariffs.
Fri Sep 26, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings